两种基因检测系统在早期乳腺癌中的研究进展
摘要
在早期乳腺癌（ESBC）如淋巴结阴性乳腺癌患者的治疗中，辅助化疗使远处转移和死亡风险降低了约50％。医师根据一些临床病理诊断标准来判断是否ESBC患者需要接受辅助内分泌治疗和／或化疗。目前ESBC的治疗指南规定：大部分淋巴结阴性、受体阳性的ESBC患者应接受辅助化疗和内分泌治疗。
出处
《癌症进展》
2009年第5期510-514,共5页
Oncology Progress
参考文献23
-
1Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 -year survival: An overview of the randomised trials [J]. Lancet, 2005, 365 : 1687.
-
2Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer [ J ]. J Clin Oncol, 2003, 21 : 3357.
-
3Carlson RW, Brown E, Burstein H J, et al. NCCN task force report: Adjuvant therapy for breast cancer [ J ]. J Natl Compr Cane Netw, 2006, 4 (Suppl 1 ): S1.
-
4van de Vijver MJ, He YD, van't Veer LJ, et al. A gene -expression signature as a predictor of survival in breast cancer [J]. N Engl J Med, 2002, 347 : 1999.
-
5Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70 - gene prognostic signature for women with node -negative breast cancer [ J ]. J Natl Cancer Inst, 2006, 98 : 1183.
-
6Wang Y, Klijn JG, Zhang Y, et al. Gene - expression profiles to predict distant metastasis of lymph - node - negative primary breast cancer [J]. Lancet, 2005, 365:671.
-
7Foekens JA, Atkins D, Zhang Y, et al. Multicenter validation of a gene expression - based prognostic signature in lymph node - negative primary breast cancer [ J ]. J Clin Oncol, 2006, 24 : 1665.
-
8Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen - treated, node - negative breast cancer [J]. N Engl J Med, 2004, 351:2817.
-
9Habel LA, Shak S, Jacobs MK, et al. A population- based study of tumor gene expression and risk of breast cancer death-among lymph node -negative patients [ J ]. Breast Cancer Res, 2006, 8 : R25.
-
10Loi S, Piccart M, Sotiriou C. The use of gene - expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response [J]. Crit Rev Oneol Hematol, 2007, 61 : 187.
-
1刘璐,廖绍光,王宁,王雅杰.ATM在淋巴结阴性乳腺癌中的表达及临床意义[J].医学研究杂志,2012,41(9):40-43. 被引量：2
-
2张斌.淋巴结阴性乳腺癌的辅助化疗[J].临床外科杂志,2000,8(5):262-263.
-
3曹道成,李鹤成,刘毅,后强,张俊坤,崔杰,邵志敏.基质金属蛋白酶-2在淋巴结阴性乳腺癌中的表达及临床意义[J].中国癌症杂志,2004,14(2):143-146. 被引量：4
-
4凌惠媛.HPV与宫颈癌发生的关联及意义[J].中国医药指南,2013,11(22):406-407. 被引量：1
-
5李永峰,吕民豪,金锋,吴云飞.腋窝淋巴结清扫总数在预测淋巴结阴性乳腺癌患者预后中的价值[J].实用肿瘤杂志,2012,27(2):129-132. 被引量：5
-
6张斌,李艳萍,马特,邹俊芝,董卫,张强,赵林.若干生物学指标对淋巴结阴性乳腺癌预后意义的评价[J].中华肿瘤杂志,2000,22(4):298-300. 被引量：15
-
7陈晓琼,张伟.人乳头瘤病毒基因型检测在宫颈病变中的应用[J].中国医药指南（学术版）,2008,6(19):8-10.
-
8王波,李洪胜.高通量基因检测系统MammaPrint与乳腺癌预后预测[J].中国癌症杂志,2012,22(1):69-73. 被引量：1
-
9曹道成,刘毅,后强,张俊坤,崔杰,李鹤成,邵志敏.MMP-2、MMP-9、Cathepsin-D在淋巴结阴性乳腺癌中的表达及其与预后的关系[J].中华普通外科杂志,2005,20(8):510-512. 被引量：3
-
10曹道成,刘毅,后强,张俊坤,崔杰,李鹤成,邵志敏.淋巴结阴性乳腺癌基质金属蛋白酶-9表达及预后价值[J].肿瘤学杂志,2004,10(6):410-412. 被引量：1
